Automation Methods Developed By Leading Vendors Will Enable Customers to Accelerate Testing and Discovery
SAN DIEGO--(BUSINESS WIRE)--May. 15, 2013-- Illumina, Inc. (NASDAQ:ILMN) today announced it is collaborating with leading providers of liquid handling robotic platforms to develop automation methods for its best-in-class TruSeq and Nextera Sample Preparation kits. Initial partners in this effort are Beckman Coulter Life Sciences, Eppendorf, Hamilton Robotics, PerkinElmer, and Tecan.
These partnerships, and the resulting methods, reflect Illumina's commitment to creating the simplest, most efficient next-generation sequencing (NGS) workflows, and represent an important step towards enabling complete, end-to-end solutions for customers.
"We are excited to work with the top automation providers to deliver solutions that can be readily implemented in the lab, thus saving time for our customers and making automation much more accessible," said Christian Henry, Senior Vice President and General Manager of Illumina's Genomic Solutions business. "TruSeq and Nextera sample preparation kits are designed with master-mixed reagents and simplified protocols to facilitate automation. In the long term, the new methods will allow more samples to be run simultaneously and with fewer errors, while freeing up resources so that customers can focus on their scientific goals."
Under the agreements, sample preparation kits sold by Illumina will be automated by the partners, who will develop, distribute and install the methods on customers' robots, as well as provide technical support. Illumina will assist during development, testing and promotion of the methods. Methods for TruSeq RNA Sample Preparation kits will be available by end of Q2 2013, with automation methods for additional TruSeq and Nextera kits to follow.
For more information, visit www.illumina.com/automation.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paying the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release contains forward looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for sample preparation kit automation methods. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
